Study identifier:D8450C00006
ClinicalTrials.gov identifier:NCT06527755
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1, Open-Label Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability of Eplontersen Following Subcutaneous Administration of a Single Dose in Healthy Chinese Volunteers
Transthyretin-mediated Amyloidosis
Phase 1
Yes
Eplontersen Solution for Injection
All
12
Interventional
18 Years - 60 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Other
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Eplontersen Single arm | - |